Intellia Therapeutics

+$0.72 (+1.14%) As of 1:42 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO
John M. Leonard
Employees
485
Headquarters
Cambridge, Massachusetts
Founded
2014

NTLA Key Statistics

Market cap
4.85B
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.68M
High today
$64.89
Low today
$62.65
Open price
$62.77
Volume
172.16K
52 Week high
$180.59
52 Week low
$37.08

NTLA News

TIMEJul 1

Jennifer Doudna on CRISPR's 10-Year Anniversary - TIME

Jennifer Doudna was staring at a computer screen filled with a string of As, Cs, Ts, and Gs—the letters that make up human DNA—and witnessing a debilitating gen

NTLA Earnings

-$1.96
-$1.31
-$0.65
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure